Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
2 authors.
Lakiea S WrightDivision of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Division of Immunology and Allergy, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Wanda PhipatanakulDivision of Immunology and Allergy, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: wanda.phipatanakul@childrens.harvard.edu.
Funding
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
Controlling and preventing Asthma progression and Severity in Kids (CASK)U01AI126614 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2016 to 2023
$21.0M
SICAS- Diversity SupplementU01AI110397 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2015 to 2020
$8.8M
AsthmaNet: Brigham and Women's Hospital & Children's Hospital BostonU10HL098102 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ISRAEL, ELLIOT, PHIPATANAKUL, WANDA · 2009 to 2015
$5.5M
ALLERGENS IN INNER-CITY SCHOOLS AND CHILDHOOD ASTHMAR01AI073964 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2008 to 2012
$4.6M
Midcareer Investigator Award: Urban School Allergen Exposures and Childhood AsthmK24AI106822 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI PHIPATANAKUL, WANDA · 2013 to 2022
$1.9M
Sleep Disordered Breathing and Asthma Morbidity in Inner City School ChildrenF32HL124919 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI WRIGHT, LAKIEA S · 2014 to 2014
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Treatment of moderate to severe pediatric asthma: Omalizumab and potential future use of monoclonal antibodies. · full record | OpenQuestion